mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2014-4-72-75mrj-578Research ArticleОБЗОРЫREVIEWSГенно-инженерные биологические препараты при эндопротезировании суставов у больных ревматоидным артритомBiological agents for endoprosthetic joint replacement in patients with rheumatoid arthritisХлабошинаВиктория НиколаевнаKhlaboshinaViktoria Nikolaevna

115522, Москва, Каширское шоссе, д. 34A

34A, Kashirskoe Shosse, Moscow Russia 115552

mdkhlaboshina@gmail.comАмирджановаВ. Н.AmirdzhanovaV. N.

115522, Москва, Каширское шоссе, д. 34A

34A, Kashirskoe Shosse, Moscow Russia 115552

mdkhlaboshina@gmail.comФГНБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201403122014847275Copyright © Хлабошина В.Н., Амирджанова В.Н., 20142014Хлабошина В.Н., Амирджанова В.Н.Khlaboshina V.N., Amirdzhanova V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/578

Эндопротезирование – широко распространенный метод лечения заболеваний суставов во всем мире. За последние несколько десятилетий частота эндопротезирования различных суставов значительно возросла – около 1,5 млн операций в год. В статье рассмотрены проблемы эндопротезирования суставов у больных ревматоидным артритом (РА), получающих генно-инженерные биологические препараты (ГИБП). Эти препараты широко используются для лечения не только ранних, но и поздних стадий заболевания, когда уже имеются показания для проведения эндопротезирования суставов, но не удается снизить активность заболевания с помощью стандартной терапии базисными противовоспалительными препаратами. Применение генно-инженерной биологической терапии позволяет повысить эффективность контроля над активностью РА в разных стадиях заболевания и улучшить функциональные показатели. Наблюдается увеличение количества пациентов, нуждающихся в эндопротезировании суставов и получающих ГИБП. Приведены данные о безопасности применения ГИБП в периоперационном периоде. Эндопротезирование суставов на фоне такой терапии позволяет уменьшить выраженность болевого синдрома, улучшить функцию оперированного сустава и качество жизни пациентов, а также оказывает влияние на течение РА и дает возможность в большей степени снизить активность заболевания и улучшить контроль над ним.

Endoprosthetic replacement is a widely used treatment for joint disease worldwide. In the past few decades, the rate of endoprosthetic replacement of different joints has substantially increased – about 1.5 million operations yearly. The paper considers the problems of endoprosthetic joint replacement in patients with rheumatoid arthritis (RA) receiving biological agents (BAs). The latter are extensively used to treat not only the early, but also late stages of the disease when there are already indications for endoprosthetic joint replacement, but the activity of the disease cannot be diminished by standard therapy with disease-modifying antirheumatic drugs. BA therapy can enhance the efficiency of monitoring the activity of RA in its different stages and improve functional parameters. There is an increase in the number of patients requiring endoprosthetic joint replacement and receiving BAs. Data on the safety of BAs used in the perioperative period are given. Endoprosthestic joint replacement during this therapy makes it possible to decrease the degree of pain syndrome, to improve the function of an operated joint and the quality of life in patients, to affect the course of RA, to lower disease activity, and to improve their monitoring.

ревматоидный артритгенно-инженерные биологические препаратыэндопротезированиеrheumatoid arthritisbiological agentsendoprosthetic replacementReferencesTeeny SM, York SC, Mesko JW, Rea RE. Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American Association of Hip and Knee Surgeons' member survey. J Arthroplasty. 2003;18:954–62. DOI: http://dx.doi.org/10.1016/j.arth.2003.09.001.Teeny SM, York SC, Mesko JW, Rea RE. Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American Association of Hip and Knee Surgeons' member survey. J Arthroplasty. 2003;18:954–62. DOI: http://dx.doi.org/10.1016/j.arth.2003.09.001.JКmsen E, Virta LJ, Hakala M, et al. The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of antirheumatic therapy: a nationwide registerbased study from 1995 through 2010. Acta Orthop. 2013 Aug;84(4):331–7. DOI: http://dx.doi.org/10.3109/17453674.2013.810519.JКmsen E, Virta LJ, Hakala M, et al. The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of antirheumatic therapy: a nationwide registerbased study from 1995 through 2010. Acta Orthop. 2013 Aug;84(4):331–7. DOI: http://dx.doi.org/10.3109/17453674.2013.810519.Weiss RJ, Stark A, Wick MC, et al. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis. 2006 Mar;65(3):335–41. Epub 2005 Aug 3. DOI: http://dx.doi.org/10.1136/ard.2005.039420.Weiss RJ, Stark A, Wick MC, et al. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis. 2006 Mar;65(3):335–41. Epub 2005 Aug 3. DOI: http://dx.doi.org/10.1136/ard.2005.039420.Khan NA, Sokka T. Declining needs for total joint replacements for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):130. DOI: 10.1186/ar3478. Epub 2011 Oct 19.Khan NA, Sokka T. Declining needs for total joint replacements for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):130. DOI: 10.1186/ar3478. Epub 2011 Oct 19.Louie GH1, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis. 2010 May;69(5):868–71. DOI: http://dx.doi.org/10.1136/ard.2009.112474. Epub 2009 Jul 5.Louie GH1, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis. 2010 May;69(5):868–71. DOI: http://dx.doi.org/10.1136/ard.2009.112474. Epub 2009 Jul 5.Courtney A, Shourt MD, Cynthia S, et al. Utilization of orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population based stud focused on rates of surgery, patient gender and mortality. J Rheumatol. 2012 March;39(3):481–5. DOI: http://dx.doi.org/10.3899/jrheum.111056.Courtney A, Shourt MD, Cynthia S, et al. Utilization of orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population based stud focused on rates of surgery, patient gender and mortality. J Rheumatol. 2012 March;39(3):481–5. DOI: http://dx.doi.org/10.3899/jrheum.111056.Den Broeder AA, Creemers MCW, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for antitumor necrosis factor: a large retrospective study. J Rheumatol. 2007 Apr;34(4):689–95.Den Broeder AA, Creemers MCW, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for antitumor necrosis factor: a large retrospective study. J Rheumatol. 2007 Apr;34(4):689–95.Hirano Y, Kojima T, Kanayama Y, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010 May;29(5):495–500. DOI: http://dx.doi.org/10.1007/s10067-009-1346-1.Hirano Y, Kojima T, Kanayama Y, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010 May;29(5):495–500. DOI: http://dx.doi.org/10.1007/s10067-009-1346-1.Hayashi M, Kojima T, Funahashi K, et al. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2012 Jun;22(3):363–9. DOI: http://dx.doi.org/10.3109/s10165-011-0527-3.Hayashi M, Kojima T, Funahashi K, et al. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2012 Jun;22(3):363–9. DOI: http://dx.doi.org/10.3109/s10165-011-0527-3.Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol. 2004 Feb;18(1):31–45. DOI: http://dx.doi.org/10.1016/j.berh.2003.09.009.Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol. 2004 Feb;18(1):31–45. DOI: http://dx.doi.org/10.1016/j.berh.2003.09.009.Suzuki M, Nishida K, Soen S, et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci. 2011 Nov;16(6):778–84. DOI: http://dx.doi.org/10.1007/s00776-011-0142-3.Suzuki M, Nishida K, Soen S, et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci. 2011 Nov;16(6):778–84. DOI: http://dx.doi.org/10.1007/s00776-011-0142-3.Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007 May–Jun;25(3):430–6.Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007 May–Jun;25(3):430–6.Fuerst M, Mö hl H, Baumgä rtel K, Rü ther W. Leflunomid increases the risk of early healing complicationes in patients with rheumatoid arthritis undergroing elective orthopaedic. Rheumatol Int. 2006;26(12):1138–42.Fuerst M, Mö hl H, Baumgä rtel K, Rü ther W. Leflunomid increases the risk of early healing complicationes in patients with rheumatoid arthritis undergroing elective orthopaedic. Rheumatol Int. 2006;26(12):1138–42.Kubota A, Nakamura T, Miyazaki Y, et al. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol. 2012 Nov;22(6):844–8. DOI: http://dx.doi.org/10.3109/s10165-012-0612-2.Kubota A, Nakamura T, Miyazaki Y, et al. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol. 2012 Nov;22(6):844–8. DOI: http://dx.doi.org/10.3109/s10165-012-0612-2.Johnson BK, Goodman SM, Alexiades MM, et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013 May;40(5):617–23. DOI: http://dx.doi.org/10.3899/jrheum.121171.Johnson BK, Goodman SM, Alexiades MM, et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013 May;40(5):617–23. DOI: http://dx.doi.org/10.3899/jrheum.121171.Hayata K, Kanbe K, Chiba J, et al. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis. 2011 Feb;14(1):31–6. DOI: http://dx.doi.org/10.1111/j.1756-185X.2010.01579.x.Hayata K, Kanbe K, Chiba J, et al. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis. 2011 Feb;14(1):31–6. DOI: http://dx.doi.org/10.1111/j.1756-185X.2010.01579.x.Hirao M, Hashimoto J, Tsuboi H, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009 May;68(5):654–7. DOI: http://dx.doi.org/10.1136/ard.2008.090068.Hirao M, Hashimoto J, Tsuboi H, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009 May;68(5):654–7. DOI: http://dx.doi.org/10.1136/ard.2008.090068.Godot S, Gottenberg JE, Paternotte S, et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1874–9. DOI: http://dx.doi.org/10.1002/acr.22056.Godot S, Gottenberg JE, Paternotte S, et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1874–9. DOI: http://dx.doi.org/10.1002/acr.22056.Погожева ЕЮ, Амирджанова ВН, Макаров СА, Насонов ЕЛ. Осложнения после эндопротезирования суставов у пациентов, получающих генно-инженерные биологические препараты. Научно-практическая ревматология. 2012;52(3):43–8. [Pogozheva EYu, Amirdzhanova VN, Makarov SA, Nasonov EL. Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;52(3):43–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-708.Погожева ЕЮ, Амирджанова ВН, Макаров СА, Насонов ЕЛ. Осложнения после эндопротезирования суставов у пациентов, получающих генно-инженерные биологические препараты. Научно-практическая ревматология. 2012;52(3):43–8. [Pogozheva EYu, Amirdzhanova VN, Makarov SA, Nasonov EL. Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;52(3):43–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-708.Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedicsurgery? A systematic review of the evidence. Rheumatol Int. 2012 Jan;32(1):5–13. DOI: http://dx.doi.org/10. 1007/s00296-011-2040-6.Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedicsurgery? A systematic review of the evidence. Rheumatol Int. 2012 Jan;32(1):5–13. DOI: http://dx.doi.org/10. 1007/s00296-011-2040-6.Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8. DOI: http://dx.doi.org/10.3109/s10165-007-0626-3.Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8. DOI: http://dx.doi.org/10.3109/s10165-007-0626-3.Bissar L, Almoallim H, Albazli K, et al. Perioperative management of patients with rheumatic diseases. Open Rheumatol J. 2013 Aug 19;7:42–50. DOI: http://dx.doi.org/10.2174/1874312901307010042.Bissar L, Almoallim H, Albazli K, et al. Perioperative management of patients with rheumatic diseases. Open Rheumatol J. 2013 Aug 19;7:42–50. DOI: http://dx.doi.org/10.2174/1874312901307010042.Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010 Jun;49(6):1197–9. DOI: http://dx.doi.org/10.1093/rheumatology/keq006a.Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010 Jun;49(6):1197–9. DOI: http://dx.doi.org/10.1093/rheumatology/keq006a.Амирджанова ВН, Макаров МА, Бялик ЕИ и др. Периоперационное ведение больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(4)366–75. [Amirdzhanova VN, Makarov MA, Byalik EI, et al. Perioperative management of patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4)366–75. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-366-375.Амирджанова ВН, Макаров МА, Бялик ЕИ и др. Периоперационное ведение больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(4)366–75. [Amirdzhanova VN, Makarov MA, Byalik EI, et al. Perioperative management of patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4)366–75. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-366-375.

The authors declare that there are no conflicts of interest present.